Eli Lilly

$218.55 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Eli Lilly

Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.

Stock Analysis

last close $223.52
1-mo return 13.9%
3-mo return 18.2%
avg daily vol. 4.35M
52-week high 235.85
52-week low 129.21
market cap. $214.9B
forward pe 27.7
annual div. 3.4
roe 122.1%
ltg forecast 12.8%
dividend yield 1.52%
annual rev. $25.5B
inst own. 83.7%
baraka

Subscribe now for daily local and international financial news

Subscribe